What is HEALTHLYNKED CORP NEW's earnings per share (EPS)?

HEALTHLYNKED CORP NEW (HLYKD) reported diluted earnings per share of -$1.16 for fiscal year 2025. This represents a 46.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

HEALTHLYNKED CORP NEW (HLYKD) Financials

HLYKD

Trailing 12 months to March 31, 2026

Revenue $1.7M -38.3% YoY

Net Income -$3.9M +33.5% YoY

EPS (Diluted) -$1.16 FY2025 annual

Operating Cash Flow -$1.5M +51.1% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 29, 2026 Currency USD FYE December

Newest figures come from the 10-K for Q1 FY2026, filed May 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HLYKD SEC filings page.

HEALTHLYNKED CORP NEW (HLYKD) reported $1.7M in revenue over the twelve months to Mar 31, 2026, down 38.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HLYKD FY2025 2026-08-30

Shrinking revenue has not removed the funding need: persistent losses coexist with liabilities exceeding assets.

Revenue fell from $5.7M in FY2023 to $2.1M in FY2025, revealing a materially smaller operating base rather than growth-driven improvement. In FY2025, a -102.3% operating margin coincided with operating cash flow of -$1.7M, showing that lower reported costs have not made the business cash-generative.

Liabilities of $7.5M were more than four times assets of $1.7M in FY2025, leaving obligations unsupported by the reported asset base. The 0.2x current ratio indicates near-term liabilities substantially exceeded near-term assets.

Financing cash inflow of $1.5M nearly offset operating cash flow of -$1.7M in FY2025, indicating that operations were not self-funding. The financing pattern helps explain how the company continued funding activity despite ongoing losses.

Financial Health Signals

Financial health score not available

HEALTHLYNKED CORP NEW does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/7

HEALTHLYNKED CORP NEW passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

HEALTHLYNKED CORP NEW reported a net loss of $3.3M while operations used $1.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$423K

YoY-45.3%

QoQ+36.5%

HEALTHLYNKED CORP NEW generated $423K in revenue in Q1 2026. This represents a decrease of 45.3% from the same quarter a year earlier. Against the prior quarter it is up 36.5%.

EBITDA

-$675K

YoY-14.5%

QoQ-33.8%

HEALTHLYNKED CORP NEW's EBITDA was -$675K in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.5% from the same quarter a year earlier. Against the prior quarter it is down 33.8%.

Net Income

-$1.6M

YoY-54.3%

QoQ-139.7%

HEALTHLYNKED CORP NEW reported -$1.6M in net income in Q1 2026. This represents a decrease of 54.3% from the same quarter a year earlier. Against the prior quarter it is down 139.7%.

EPS (Diluted)

-$0.56

HEALTHLYNKED CORP NEW earned -$0.56 per diluted share (EPS) in Q1 2026.

Cash & Balance Sheet

Cash & Debt

$24K

YoY+7.6%

QoQ-35.4%

5Y CAGR-62.7%

HEALTHLYNKED CORP NEW held $24K in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ+2.6%

5Y CAGR-58.0%

HEALTHLYNKED CORP NEW had 3M shares outstanding in Q1 2026. Against the prior quarter it is up 2.6%.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q1 2026.

Capital Allocation

None of these metrics is reported for Q1 2026.

HLYKD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HLYKD quarterly income statement

Metric	TTM	FY2510-K	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Revenue	$1.7M	$2.1M-31.3%	$3.0M-47.4%	$5.7M-2.3%	$5.9M-9.8%	$6.5M+5.9%	$6.1M+52.6%	$4.0M+77.9%	$2.3M+7.4%	$2.1M	N/A
SG&A Expenses	$2.3M	$2.0M-33.0%	$3.0M-16.1%	$3.6M-20.8%	$4.6M-7.1%	$4.9M+60.9%	$3.1M+5.1%	$2.9M+2.5%	$2.8M+53.9%	$1.8M+19.8%	$1.5M
Operating Income	-$2.2M	-$2.1M+54.8%	-$4.7M-12.7%	-$4.2M+52.1%	-$8.7M-62.4%	-$5.3M-73.5%	-$3.1M+4.3%	-$3.2M-8.0%	-$3.0M-65.9%	-$1.8M-52.5%	-$1.2M
EBITDA	N/A	-$2.0M+54.2%	-$4.4M-15.7%	-$3.8M+51.5%	-$7.8M-73.9%	-$4.5M-59.4%	-$2.8M+9.9%	-$3.1M-6.4%	-$2.9M-66.8%	-$1.8M-52.7%	-$1.2M
Interest Expense	N/A	N/A	N/A	$21K	$0	N/A	N/A	$244K+26.4%	$193K+93.8%	$100K+172.1%	$37K
Net Income	-$3.9M	-$3.3M+46.5%	-$6.1M-505.8%	-$1.0M+88.5%	-$8.8M+15.3%	-$10.4M-80.9%	-$5.8M-4.1%	-$5.5M+4.5%	-$5.8M-124.4%	-$2.6M-87.5%	-$1.4M
EPS (Basic)	N/A	-$1.16+46.8%	-$2.18	$0.00+100.0%	-$0.04+20.0%	-$0.05-25.0%	-$0.04+33.3%	-$0.06+14.3%	-$0.07-75.0%	-$0.04-100.0%	-$0.02
EPS (Diluted)	—	-$1.16+46.8%	-$2.18	$0.00+100.0%	-$0.04+20.0%	-$0.05-25.0%	-$0.04	-$0.06+14.3%	-$0.07-75.0%	-$0.04-100.0%	-$0.02
Diluted Shares (Avg)	N/A	3M+0.7%	3M	263M+8.0%	243M+8.4%	225M+57.3%	143M	99M+25.7%	79M+13.3%	70M+15.9%	60M

Metric	Q1'2610-K	Q4'2510-K	Q3'2510-Q	Q2'25	Q1'2510-K	Q4'2410-K	Q3'24	Q2'24
Revenue	$423K-45.3%	$310K-49.9%	$389K-34.2%	$592K-25.5%	$774K-22.9%	$619K-33.5%	$590K-55.7%	$795K-53.3%
SG&A Expenses	$847K+34.6%	$454K-17.0%	$501K-20.7%	$452K-47.6%	$629K-37.0%	$546K-40.5%	$632K-17.7%	$861K+3.3%
Operating Income	-$701K-13.5%	-$531K+29.1%	-$530K+68.3%	-$435K+59.7%	-$617K+47.6%	-$749K+32.7%	-$1.7M-41.1%	-$1.1M-35.3%
EBITDA	-$675K-14.5%	-$504K+30.0%	-$509K+67.9%	-$408K+58.9%	-$589K+46.0%	-$720K+29.6%	-$1.6M-44.8%	-$994K-40.1%
Net Income	-$1.6M-54.3%	-$676K+45.0%	-$852K+56.8%	-$701K+54.5%	-$1.1M+24.3%	-$1.2M+4.3%	-$2.0M-1028.0%	-$1.5M-53.5%
EPS (Basic)	-$0.56-51.4%	N/A	-$0.30+57.1%	$0.00+100.0%	-$0.37	N/A	-$0.70	-$0.01
EPS (Diluted)	-$0.56	N/A	-$0.30	$0.00+100.0%	-$0.37	N/A	-$0.70	-$0.01
Diluted Shares (Avg)	3M	N/A	3M	282M+0.1%	3M-99.0%	N/A	3M-98.9%	282M+8.5%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Interest Expense, Income Tax.

HLYKD Balance Sheet

HLYKD quarterly balance sheet

Metric	FY2510-K	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Total Assets	$1.7M-23.4%	$2.2M-48.1%	$4.3M-6.6%	$4.6M-57.2%	$10.7M+33.2%	$8.0M+215.2%	$2.5M+495.9%	$427K-2.8%	$440K+33.5%	$330K
Current Assets	$1.6M-5.5%	$1.6M+150.1%	$656K-69.4%	$2.1M-41.3%	$3.7M+804.6%	$404K+0.2%	$403K+7.3%	$375K+2.3%	$367K+47.3%	$249K
Cash & Equivalents	$37K-51.3%	$76K-69.2%	$247K+299.4%	$62K-98.1%	$3.3M+1929.6%	$162K+46.9%	$110K-18.7%	$136K+171.5%	$50K-14.8%	$59K
Short-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Inventory	$18K-59.8%	$45K-66.5%	$133K-30.9%	$193K+42.9%	$135K+41.7%	$95K+35.1%	$70K	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$21K-71.1%	$72K-16.2%	$86K-1.0%	$87K+4.7%	$83K-27.5%	$115K+1.4%	$113K-22.8%	$147K
Long-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$320K-58.2%	$766K-33.3%	$1.1M+1497.6%	$72K	N/A	N/A	N/A
Total Liabilities	$7.5M+39.5%	$5.4M+54.0%	$3.5M-18.5%	$4.3M+22.2%	$3.5M-47.7%	$6.7M+23.9%	$5.4M+60.3%	$3.4M+35.0%	$2.5M+100.7%	$1.2M
Current Liabilities	$7.0M+49.5%	$4.7M+94.4%	$2.4M-30.6%	$3.5M+81.2%	$1.9M-60.7%	$4.9M-0.5%	$4.9M+46.1%	$3.4M+36.0%	$2.5M+156.1%	$964K
Non-Current Liabilities	$451K-31.9%	$662K-37.7%	$1.1M+34.3%	$792K-49.7%	$1.6M-12.4%	$1.8M+273.5%	$481K+15613.2%	$3K-85.7%	$21K-92.3%	$277K
Long-Term Debt	N/A	N/A	N/A	$45K-55.6%	$101K+464.3%	$18K	N/A	$3K-85.7%	$21K-46.2%	$40K
Total Equity	-$5.8M-84.1%	-$3.1M-488.9%	$805K+155.9%	$314K-95.6%	$7.2M+433.6%	$1.4M+147.5%	-$2.8M+3.1%	-$2.9M-43.1%	-$2.1M-125.0%	-$912K
Retained Earnings	-$50.5M-4.9%	-$48.2M-14.6%	-$42.0M-2.5%	-$41.0M-27.4%	-$32.2M-47.8%	-$21.8M-35.9%	-$16.0M-52.6%	-$10.5M-123.2%	-$4.7M-121.5%	-$2.1M

Metric	Q1'2610-K	Q4'2510-K	Q3'2510-Q	Q2'25	Q1'2510-K	Q4'2410-K	Q3'24	Q2'24
Total Assets	$1.6M-21.0%	$1.7M-23.4%	$1.8M-36.0%	$1.8M-52.1%	$2.1M-47.1%	$2.2M-48.1%	$2.8M-51.5%	$3.9M-25.8%
Current Assets	$1.5M-1.8%	$1.6M-5.5%	$1.5M-15.4%	$1.6M-22.3%	$1.6M-17.3%	$1.6M+150.1%	$1.8M-17.1%	$2.0M+11.9%
Cash & Equivalents	$24K+7.6%	$37K-51.3%	$11K-27.1%	$20K-88.3%	$22K-5.2%	$76K-69.2%	$15K-70.9%	$173K-81.2%
Inventory	$18K-42.7%	$18K-59.8%	$32K-59.4%	$28K-71.4%	$32K-76.3%	$45K-66.5%	$79K-44.6%	$96K-38.4%
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$26K-38.5%	$39K-0.3%
Total Liabilities	$8.6M+39.6%	$7.5M+39.5%	$7.2M+53.4%	$6.6M+54.1%	$6.2M+68.8%	$5.4M+54.0%	$4.7M+13.6%	$4.3M+8.4%
Current Liabilities	$8.2M+46.4%	$7.0M+49.5%	$6.7M+77.2%	$6.1M+80.4%	$5.6M+107.8%	$4.7M+94.4%	$3.8M+13.3%	$3.4M+2.3%
Non-Current Liabilities	$450K-24.4%	$451K-31.9%	$454K-48.7%	$475K-46.6%	$595K-38.9%	$662K-37.7%	$884K+15.2%	$889K+40.1%
Total Equity	-$7.0M-69.7%	-$5.8M-84.1%	-$5.4M-181.1%	-$4.8M-1019.3%	-$4.1M-1967.9%	-$3.1M-488.9%	-$1.9M-223.8%	-$425K-127.0%
Retained Earnings	-$52.2M-6.1%	-$50.5M-4.9%	-$50.8M-8.2%	-$49.9M-11.0%	-$49.2M-13.3%	-$48.2M-14.6%	-$46.9M-15.2%	-$45.0M-10.8%

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill, Long-Term Debt.

HLYKD Cash Flow Statement

HLYKD quarterly cash flow statement

Metric	TTM	FY2510-K	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Operating Cash Flow	-$1.5M	-$1.7M+51.0%	-$3.5M+15.7%	-$4.1M+5.0%	-$4.4M-15.7%	-$3.8M-78.1%	-$2.1M+10.4%	-$2.4M-0.3%	-$2.4M-45.5%	-$1.6M-114.1%	-$756K
Depreciation & Amortization	N/A	$102K-64.0%	$283K-19.6%	$352K-57.6%	$829K+0.2%	$828K+234.6%	$247K+237.1%	$73K+208.6%	$24K+0.7%	$24K+43.4%	$16K
Stock-Based Compensation	N/A	$159K-24.6%	$210K-30.8%	$304K+204.0%	$100K	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	$3K+73.2%	$2K-93.6%	$24K+22.4%	$19K-23.0%	$25K+148.6%	$10K+235.0%	$3K-81.4%	$16K+28.0%	$13K
Free Cash Flow	N/A	N/A	-$3.5M+15.7%	-$4.1M+5.5%	-$4.4M-15.8%	-$3.8M-76.9%	-$2.1M+9.7%	-$2.4M-0.6%	-$2.4M-44.3%	-$1.6M-112.7%	-$769K
Investing Cash Flow	N/A	$125K-70.4%	$422K-88.0%	$3.5M+743.6%	-$545K-59.6%	-$341K-118.8%	$1.8M+481.5%	-$475K-15724.7%	-$3K+81.4%	-$16K-28.0%	-$13K
Financing Cash Flow	$1.4M	$1.5M-46.6%	$2.9M+252.0%	$824K-50.9%	$1.7M-76.8%	$7.2M+1929.3%	$357K-87.3%	$2.8M+15.0%	$2.4M+50.3%	$1.6M+103.9%	$798K
Dividends Paid	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$8K	N/A	$1K	N/A	N/A	N/A

Metric	Q1'2610-K	Q4'2510-K	Q3'2510-Q	Q2'25	Q1'2510-K	Q4'2410-K	Q3'24	Q2'24
Operating Cash Flow	-$222K+48.7%	-$419K+43.6%	-$444K+57.2%	-$418K+51.4%	-$433K+49.4%	-$744K+37.6%	-$1.0M+17.0%	-$859K-42.2%
Depreciation & Amortization	$26K-7.1%	$26K-7.0%	$20K-75.6%	$27K-68.1%	$28K-67.6%	$28K-67.8%	$83K-5.3%	$85K-3.4%
Stock-Based Compensation	$298K+4075.2%	N/A	$5K+2294.9%	N/A	$7K-92.3%	N/A	$196	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$744K+37.6%	-$1.0M	-$859K
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$425K-64.2%	$0-100.0%	$0-100.0%
Financing Cash Flow	$209K-44.8%	$321K-15.6%	$435K-50.5%	$415K-58.8%	$379K-40.3%	$380K+88.1%	$879K+3693.9%	$1.0M+267.8%
Dividends Paid	$36K	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Share Buybacks.

HLYKD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HLYKD quarterly financial ratios

Metric	FY2510-K	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Operating Margin	-102.3%	-155.5%	-72.5%	-147.8%	-82.0%-32.0pp	-50.1%+29.8pp	-79.8%	-131.6%	-85.2%	N/A
Net Margin	-158.8%	-203.8%	-17.7%	-150.5%	-160.3%	-93.8%	-137.6%	-256.3%	-122.7%	N/A
Return on Equity	N/A	N/A	-125.8%+2677.8pp	-2803.5%-2659.0pp	-144.5%+281.8pp	-426.3%	N/A	N/A	N/A	N/A
Return on Assets	-192.7%+83.1pp	-275.8%-252.2pp	-23.6%+168.8pp	-192.5%-95.1pp	-97.4%-25.7pp	-71.7%+145.4pp	-217.1%+1137.9pp	-1355.0%-768.1pp	-586.9%-169.2pp	-417.7%
Current Ratio	0.22-0.1x	0.35+0.1x	0.27-0.3x	0.62-1.3x	1.90+1.8x	0.080.0x	0.080.0x	0.110.0x	0.15-0.1x	0.26
Debt-to-Equity	N/A	N/A	4.32+4.2x	0.14+0.1x	0.010.0x	0.01	N/A	N/A	N/A	N/A
Asset Turnover	1.21-0.1x	1.350.0x	1.34+0.1x	1.28+0.7x	0.61-0.2x	0.76-0.8x	1.58-3.7x	5.29+0.5x	4.78	N/A
FCF Margin	N/A	-116.2%	-72.5%+2.4pp	-74.9%-16.6pp	-58.3%-23.4pp	-34.9%+24.1pp	-59.0%	-104.4%	-77.7%	N/A

Metric	Q1'2610-K	Q4'2510-K	Q3'2510-Q	Q2'25	Q1'2510-K	Q4'2410-K	Q3'24	Q2'24
Operating Margin	-165.5%	-171.2%	-136.3%	-73.5%	-79.7%	-121.0%	-283.2%	-135.8%
Net Margin	-382.9%	-218.1%	-219.2%	-118.3%	-135.7%	-198.8%	-334.4%	-193.8%
Return on Assets	-99.7%-48.6pp	-39.7%+15.6pp	-48.3%+23.3pp	-37.9%+2.0pp	-51.1%-15.4pp	-55.3%-25.3pp	-71.5%-68.5pp	-39.9%-20.6pp
Current Ratio	0.19-0.1x	0.22-0.1x	0.23-0.3x	0.25-0.3x	0.28-0.4x	0.35+0.1x	0.48-0.2x	0.59+0.1x
Asset Turnover	0.26-0.1x	0.18-0.1x	0.220.0x	0.32+0.1x	0.38+0.1x	0.28+0.1x	0.210.0x	0.21-0.1x
FCF Margin	N/A	N/A	N/A	N/A	N/A	-120.1%	-175.7%	-108.0%

Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$5.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.22), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Where HEALTHLYNKED CORP NEW Ranks

Frequently Asked Questions

What is HEALTHLYNKED CORP NEW's annual revenue?

HEALTHLYNKED CORP NEW (HLYKD) reported $2.1M in total revenue for fiscal year 2025. This represents a -31.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is HEALTHLYNKED CORP NEW's revenue growing?

HEALTHLYNKED CORP NEW (HLYKD) revenue declined by 31.3% year-over-year, from $3.0M to $2.1M in fiscal year 2025.

Is HEALTHLYNKED CORP NEW profitable?

No, HEALTHLYNKED CORP NEW (HLYKD) reported a net income of -$3.3M in fiscal year 2025.

What is HEALTHLYNKED CORP NEW's EBITDA?

HEALTHLYNKED CORP NEW (HLYKD) had EBITDA of -$2.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is HEALTHLYNKED CORP NEW's operating cash flow?

HEALTHLYNKED CORP NEW (HLYKD) recorded an outflow of $1.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are HEALTHLYNKED CORP NEW's total assets?

HEALTHLYNKED CORP NEW (HLYKD) had $1.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does HEALTHLYNKED CORP NEW have outstanding?

HEALTHLYNKED CORP NEW (HLYKD) had 3M shares outstanding as of fiscal year 2025.

What is HEALTHLYNKED CORP NEW's current ratio?

HEALTHLYNKED CORP NEW (HLYKD) had a current ratio of 0.22 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is HEALTHLYNKED CORP NEW's return on assets (ROA)?

HEALTHLYNKED CORP NEW (HLYKD) had a return on assets of -192.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is HEALTHLYNKED CORP NEW's debt-to-equity ratio negative or not reported?

HEALTHLYNKED CORP NEW (HLYKD) has negative shareholder equity of -$5.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is HEALTHLYNKED CORP NEW's Piotroski F-Score?

HEALTHLYNKED CORP NEW (HLYKD) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are HEALTHLYNKED CORP NEW's earnings high quality?

HEALTHLYNKED CORP NEW (HLYKD) reported a net loss of $3.3M while operations used $1.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.